Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 16,194 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active-Control Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing

NCT05418894
View directory record Official record
Conditions
Treatment Resistant Depression, Epilepsy
Interventions
Device: Directional Deep Brain Stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
22 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Not applicable Interventional Results available

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

NCT01577966
View directory record Official record
Conditions
Brain Tumor
Interventions
Sulfasalazine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 26, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional

Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma

NCT06278922
View directory record Official record
Conditions
PTSD, Alcohol; Use, Problem
Interventions
Seeking Safety + Signs of Safety toolkit, Treatment as usual
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 4 Interventional Results available

Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils

NCT02023151
View directory record Official record
Conditions
Allergic Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 26, 2026, 10:51 AM EDT
Not listed Phase 4 Interventional

Does Clinical Response Correlate With Serum Certolizumab Levels?

NCT02597829
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors

NCT02938780
View directory record Official record
Conditions
Breast Cancer Female
Interventions
placebo text message, nutrition physical activity text message
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
20 Years to 75 Years · Female only
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 26, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Intraoral Transcutaneous Electrical Nerve Stimulation in Orthodontics Pain

NCT06573996
View directory record Official record
Conditions
Orthodontic Appliance, Pain, Transcutaneous Electric Nerve Stimulation, Orthodontic Appliance Complication
Interventions
Active TENS Device, Intervention 2: Placebo/Sham Device
Device
Lead sponsor
University of the Pacific
Other
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy

NCT01895062
View directory record Official record
Conditions
Airway Obstruction, Apnea, Hypopnea
Interventions
Airway Management System (AMS)
Device
Lead sponsor
5i Sciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 26, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comprehensive Outcomes for After Cancer Health

NCT05349227
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Interventions
Digital Health Coaching Program, Fitbit
Behavioral · Device
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

NCT01863186
View directory record Official record
Conditions
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Interventions
Lofexidine HCl, Placebo, Open Label Lofexidine HCL
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Clovis, California • Escondido, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Not applicable Interventional Results available

Cocaine Withdrawal and Pharmacotherapy Response

NCT00566969
View directory record Official record
Conditions
Cocaine Dependence, Opiate Dependence
Interventions
sugar pill, Carvedilol 25 mg, Carvedilol 50 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

NCT00779883
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ISF35
Biological
Lead sponsor
Memgen, LLC
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2008 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor

NCT02566005
View directory record Official record
Conditions
Pregnancy
Interventions
misoprostol, Foley bulb
Device
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Not applicable Interventional Results available

Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)

NCT05020366
View directory record Official record
Conditions
Down Syndrome
Interventions
Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Months and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 26, 2026, 10:51 AM EDT
Recruiting Phase 3 Interventional

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931
View directory record Official record
Conditions
Crohn's Disease
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
127
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional

Transcranial Direct Current Stimulation (tDCS) in Chronic Stroke Recovery

NCT01014897
View directory record Official record
Conditions
Stroke
Interventions
tDCS
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Not applicable Interventional

Incorporating Acupuncture Into ERAS for Ambulatory Total Hip Replacement (THR) Surgery

NCT05384860
View directory record Official record
Conditions
Acupuncture, Hip Surgery, Opioid Use
Interventions
Auricular Trauma Protocol (ATP) Acupuncture, No Acupuncture Group
Device · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 26, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

NCT06662162
View directory record Official record
Conditions
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
i-Lumen AMD
Device
Lead sponsor
i-Lumen Scientific AUS PTY LTD
Industry
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Poway, California • Manchester, Connecticut • Lemont, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

NCT03691727
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam, Questionnaires, Vital Signs, Standard of Care Treatment
Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor
David Hasan
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 26, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

NCT01482286
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Dietary Restriction, Exercise Training
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 26, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 26, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 26, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283
View directory record Official record
Conditions
Atrial Fibrillation (AF), Stroke
Interventions
Abelacimab, Rivaroxaban
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 26, 2026, 10:51 AM EDT